These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 36153007)
1. Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling. Wen B; Zhang Y; Young GC; Kenworthy D; Pereira A; Pirhalla J; Doyle J; Jordon B; Zhan J; Johnson M Drug Metab Dispos; 2022 Nov; 50(11):1442-1453. PubMed ID: 36153007 [TBL] [Abstract][Full Text] [Related]
2. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and ADME Characterization of Intravenous and Oral [ Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435 [TBL] [Abstract][Full Text] [Related]
4. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects. Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068 [TBL] [Abstract][Full Text] [Related]
5. The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor. Takahashi RH; Malhi V; Liederer BM; Cho S; Deng Y; Dean B; Nugteren J; Yost E; Al-Sayah MA; Sane R; Kshirsagar S; Ma S; Musib L Drug Metab Dispos; 2023 Oct; 51(10):1332-1341. PubMed ID: 37524543 [TBL] [Abstract][Full Text] [Related]
6. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans. Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects. Darwish M; Nunez R; Youakim JM; Robertson P Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349 [TBL] [Abstract][Full Text] [Related]
8. Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects. Lindmark B; Li XQ; Bhattacharya C; Housler G; Heijer M; Bragg RA; Gränfors M; Pelay-Gimeno M; Vaes WHJ; Menakuru S; Pizzato PE; Ericsson H; Johansson S Drug Metab Dispos; 2023 Aug; 51(8):995-1004. PubMed ID: 37407094 [TBL] [Abstract][Full Text] [Related]
9. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans. Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983 [TBL] [Abstract][Full Text] [Related]
10. A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a Qiu R; Sharma R; Wei H; Kirkovsky L; Zhou Y; Martin DDA; Banfield C; Dowty ME Br J Clin Pharmacol; 2023 Oct; 89(10):3056-3066. PubMed ID: 37183779 [TBL] [Abstract][Full Text] [Related]
11. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745. Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741 [TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination. Mahar KM; Caltabiano S; Andrews S; Ramanjineyulu B; Chen L; Young G; Pereira A; Lindsay AC; van den Berg F; Cobitz AR Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1419-1431. PubMed ID: 34713596 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795 [TBL] [Abstract][Full Text] [Related]
14. A Phase I Study To Determine the Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Capivasertib in Healthy Male Participants. Miller C; Wild M; Zhang Z; Sommavilla R; Shanahan D; Bailey C; Gränfors M; Bragg RA; Dong J; Sidhu S; Cullberg M Drug Metab Dispos; 2024 Aug; 52(9):939-948. PubMed ID: 39029948 [TBL] [Abstract][Full Text] [Related]
15. Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string. Tai G; Xia F; Chen C; Pereira A; Pirhalla J; Miao X; Young G; Beaumont C; Chen L Pharmacol Res Perspect; 2023 Dec; 11(6):e1145. PubMed ID: 37885335 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, absorption, metabolism, and excretion of [ Prakash C; Fan B; Altaf S; Agresta S; Liu H; Yang H Cancer Chemother Pharmacol; 2019 May; 83(5):837-848. PubMed ID: 30758648 [TBL] [Abstract][Full Text] [Related]
17. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans. Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002 [TBL] [Abstract][Full Text] [Related]
18. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Disposition, and Biotransformation of [ Weber E; Subramanian R; Rowe W; Graupe M; Ling J; Shen G; Begley R; Sager J; Wolckenhauer S; Rhee M; Palaparthy R; Singh R Clin Pharmacokinet; 2024 Feb; 63(2):241-253. PubMed ID: 38236562 [TBL] [Abstract][Full Text] [Related]
20. Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects. Kshirsagar S; Chen YC; Yu J; Gates MR; Kawakatsu S; Khojasteh SC; Ma S; Musib L; Malhi V; Osaghae U; Wang J; Cho S; Tang YT; Zhang D; Zhao W; De Bruyn T Drug Metab Dispos; 2024 Jul; 52(8):847-857. PubMed ID: 38834357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]